Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study"/>

Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study

1 Sept

Written By Carla Aguilera

Keith Holmes, Ulrike Pötschger, Andrew D J Pearson, Sabine Sarnacki, Giovanni Cecchetto, Javier Gomez-Chacon, Roly Squire, Enrique Freud, Adam Bysiek, Lucas E Matthyssens, Martin Metzelder, Tom Monclair, Jakob Stenman, Michal Rygl, Lars Rasmussen, Jean-Marc Joseph, Sabine Irtan, Stefano Avanzini, Jan Godzinski, Kristin Björnland, Martin Elliott, Roberto Luksch, Victoria Castel, Shifra Ash, Walentyna Balwierz, Geneviève Laureys, Ellen Ruud, Vassilios Papadakis, Josef Malis, Cormac Owens, Henrik Schroeder, Maja Beck-Popovic, Toby Trahair, Ana Forjaz de Lacerda, Peter F Ambros, Mark N Gaze, Kieran McHugh, Dominique Valteau-Couanet, Ruth Lydia Ladenstein; International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN)

J Clin Oncol. 2020 Sep 1;38(25):2902-2915. PMID: 32639845. DOI: 10.1200/JCO.19.03117

2020

Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas.

Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from ITCC and SIOPEN